{"id":"NCT04436510","sponsor":"Merit E. Cudkowicz, MD","briefTitle":"HEALEY ALS Platform Trial - Regimen B Verdiperstat","officialTitle":"HEALEY ALS Platform Trial - Regimen B Verdiperstat","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2020-07-28","primaryCompletion":"2022-04-13","completion":"2022-12-06","firstPosted":"2020-06-18","resultsPosted":"2023-06-12","lastUpdate":"2023-06-12"},"enrollment":167,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Amyotrophic Lateral Sclerosis"],"interventions":[{"type":"DRUG","name":"Matching Placebo","otherNames":[]},{"type":"DRUG","name":"Verdiperstat","otherNames":[]}],"arms":[{"label":"Verdiperstat","type":"EXPERIMENTAL"},{"label":"Matching Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.\n\nRegimen B will evaluate the safety and efficacy of a single study drug, verdiperstat, in participants with ALS.","primaryOutcome":{"measure":"Disease Progression as Assessed by the ALSFRS-R-Slope","timeFrame":"Baseline to 24 Weeks","effectByArm":[{"arm":"Verdiperstat","deltaMin":-1.02,"sd":0.091},{"arm":"Matching Placebo","deltaMin":-1.05,"sd":0.086}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["40067754"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":126},"commonTop":["Nausea","Headache","Muscular weakness","Fall","Constipation"]}}